U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07336147) titled 'Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma' on Dec. 29, 2025.
Brief Summary: Add-on dostarlimab to chemoradiation with etoposide and cisplatin and radiotherapy can improve progression-free survival (PFS) compared with historical controls who were treated with chemoradiation alone in SCNECC
Study Start Date: Dec. 22, 2025
Study Type: INTERVENTIONAL
Condition:
Female
Intervention:
DRUG: Dostarlimab
The planned dose of dostarlimab for this study is 500 mg every 3 weeks (Q3W) during chemoimmunotherapy phase. Based on the totality of d...